Amid a flurry of newly-published guidelines on biosimilars and biologic drugs, US Food and Drug Administration (FDA) Commissioner Scott Gottlieb has set out his vision for the future of the US biosimilars market.
Referring to the US small-molecule generics market as “one of the most competitive generics markets in the world”, Gottlieb acknowledged...






